• LivaNova posted Q2 revenue of $390.6 million, up 10.8% from a year earlier; U.S. GAAP diluted EPS rose to $1.93.
• Adjusted diluted EPS increased to $1.26; U.S. GAAP operating income slipped to $49.5 million.
• Cardiopulmonary revenue climbed 11.2% to $221.6 million; Neuromodulation revenue rose 10.1% to $166.9 million.
• Signed a long-term deal with Thermo Fisher Scientific to boost supply of a critical oxygenator component as it works to lift output.
• Raised 2026 constant-currency revenue growth guidance to 8%-9%; lifted adjusted diluted EPS outlook to $4.30-$4.40.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.